课题基金 / 基金详情

Marek's disease, a lymphoma caused by herpesvirus-replication dynamics, pathogenesis and vaccine effect

Marek's disease, a lymphoma caused by herpesvirus-replication dynamics, pathogenesis and vaccine effect
马立克氏病,一种由疱疹病毒引起的淋巴瘤——复制动态、发病机制和疫苗效果
批准号:
356287-2009
负责人:
Niikura, Masahiro
金额:
$2.33万
依托单位:
依托单位国家:
加拿大
项目类别:
Discovery Grants Program - Individual
财政年份:
2009
资助国家:
加拿大
项目状态:
已结题
起止时间:
2009-01-01 至 2010-12-31

项目摘要

项目成果

Niikura, Masahiro的其他基金

相似基金

相关文献

中文摘要
翻译
马立克氏病病毒(MDV)引起马立克氏病(MD),一种家禽淋巴瘤。 MDV在全球普遍存在,因此几乎所有的商业鸡都接种了MD疫苗。MD在未接种疫苗的鸡群中的发病率可高达20- 30%;这在20世纪70年代早期引入MD疫苗之前是常见的。MD疫苗的不寻常之处在于它不能预防强毒MDV感染,而是疫苗病毒在与宿主中的强毒病毒共存时预防肿瘤形成。发生这种情况的机制还不清楚。MD肿瘤细胞携带MDV基因组,这意味着肿瘤细胞被病毒感染。由于MD肿瘤细胞不被MDV感染杀死,因此它们必须被潜伏感染。否则,MDV会杀死溶解性感染的细胞。检测这些潜伏感染的细胞非常困难,因为MDV在潜伏期间仅产生少数病毒特异性蛋白质和RNA。然而,为了了解MD的发病机制和疫苗接种机制,了解溶解性和潜伏性感染的动态是至关重要的。
英文摘要
Marek's disease virus (MDV) causes Marek's disease (MD), a lymphoma of poultry. MDV is globally ubiquitous, thus almost all commercial chickens are vaccinated with the MD vaccine. Incidence of MD in unvaccinated chicken flocks can be as high as 20-30 %; this was commonly observed before the introduction of MD vaccines in the early 1970's. The MD vaccine is unusual in that it does not prevent virulent MDV infection, but rather the vaccine virus prevents tumor formation while co-existing with the virulent virus in the host. The mechanism by which this occurs is not well understood. MD tumor cells harbor the MDV genome, which means the tumor cells are infected with virus. Since MD tumor cells are not killed by the MDV infection, they must be infected latently. Otherwise MDV kills the lytically infected cells. It is very difficult to detect these latently infected cells as MDV makes only a few virus specific proteins and RNAs during latency. However, it is essential to know the dynamics of both lytic and latent infection in order to understand the pathogenesis and vaccination mechanisms in MD.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Marek's disease avian herpesvirus - Learning from differences
  • 批准号:
    RGPIN-2022-03680
  • 项目类别:
    Discovery Grants Program - Individual
  • 资助金额:
    $2.33万
  • 财政年份:
    2022
  • 负责人:
    Niikura, Masahiro
  • 依托单位:
Enhancement of immunogenicity by increased retention of antigenic proteins to injection sites and multimerization
  • 批准号:
    531113-2018
  • 项目类别:
    Collaborative Research and Development Grants
  • 资助金额:
    $1.86万
  • 财政年份:
    2019
  • 负责人:
    Niikura, Masahiro
  • 依托单位:
Enhancement of immunogenicity by increased retention of antigenic proteins to injection sites and multimerization
  • 批准号:
    531113-2018
  • 项目类别:
    Collaborative Research and Development Grants
  • 资助金额:
    $1.78万
  • 财政年份:
    2018
  • 负责人:
    Niikura, Masahiro
  • 依托单位:
Marek's disease, a lymphoma caused by herpesvirus-replication dynamics, pathogenesis and vaccine effect
  • 批准号:
    356287-2009
  • 项目类别:
    Discovery Grants Program - Individual
  • 资助金额:
    $2.33万
  • 财政年份:
    2013
  • 负责人:
    Niikura, Masahiro
  • 依托单位:
国内基金
海外基金
黏液层/细菌被膜双重渗透型抗菌聚多肽纳米载体用于肺部给药治疗慢性阻塞性肺病
  • 批准号:
  • 项目类别:
    省市级项目
  • 资助金额:
    --
  • 批准年份:
    2024
  • 负责人:
    虞桂平
  • 依托单位:
Got2基因对浆细胞样树突状细胞功能的调控及其在系统性红斑狼疮疾病中的作用研究
  • 批准号:
    82371801
  • 项目类别:
    面上项目
  • 资助金额:
    47.00万元
  • 批准年份:
    2023
  • 负责人:
    周海波
  • 依托单位:
Erk1/2/CREB/BDNF通路在CSF1R相关性白质脑病致病机制中的作用研究
  • 批准号:
    82371255
  • 项目类别:
    面上项目
  • 资助金额:
    49.00万元
  • 批准年份:
    2023
  • 负责人:
    曹立
  • 依托单位:
肠道菌群介导的脱氧胆酸激活S1PR2/NLRP3/IL-1β通路在炎症性肠病合并艰难梭菌感染中的致病机制研究
  • 批准号:
    82372306
  • 项目类别:
    面上项目
  • 资助金额:
    48.00万元
  • 批准年份:
    2023
  • 负责人:
    彭奕冰
  • 依托单位: